STATEMENTS OF STOCKHOLDERS' (DEFICIT) - USD ($)	Common Stock	Additional Paid-in Capital	Retained Deficit	Total
Balance at Feb. 28, 2023	$ 131,449	$ 126,609,599	$ (126,754,775)	$ (13,727)
Balance (in shares) at Feb. 28, 2023	131,448,444
Increase (Decrease) in Stockholders' Equity
Cash contributed by S.R. Burzynski M.D., Ph.D.		524,156		524,156
FDA clinical trial expenses paid directly by S.R. Burzynski M.D., Ph.D.		799,879		799,879
Net loss			(1,335,431)	(1,335,431)
Balance at Feb. 29, 2024	$ 131,449	127,933,634	(128,090,206)	(25,123)
Balance (in shares) at Feb. 29, 2024	131,448,444
Increase (Decrease) in Stockholders' Equity
Cash contributed by S.R. Burzynski M.D., Ph.D.		388,068		388,068
FDA clinical trial expenses paid directly by S.R. Burzynski M.D., Ph.D.		981,625		981,625
Net loss			(1,386,207)	(1,386,207)
Balance at Feb. 28, 2025	$ 131,449	$ 129,303,327	$ (129,476,413)	$ (41,637)
Balance (in shares) at Feb. 28, 2025	131,448,444